Drugs / Ibezapolstat
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07513285 | Aug 2026 → Sep 2027 expected | Clostridium difficile colitis | Acurx Pharmaceuticals Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04247542 | Mar 2020 → Oct 2023 | Clostridium infectious disease | Acurx Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ibezapolstat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04247542 ↗ |
| Known as | ACX-362E | ChEMBL registry synonym — accepted as the source's own label CHEMBL4571518 ↗ |
| Action | Inhibit | “ibezapolstat, an antibiotic that inhibits the PolC-type DNA polymerase III α subunit C” PMID 40516571 ↗ Jun 2025 |
| Modality | Small molecule | — CHEMBL4571518 ↗ |
| Route | Oral | “Patients were treated with 450 mg of oral ibezapolstat twice daily for 10 days.” NCT04247542 ↗ |